Federal regulators, working with patients, academics and pharmaceutical companies, are listing dozens of potential research projects they believe would help shorten the time it takes for new drugs to reach patients.
Federal regulators, working with patients, academics and pharmaceutical companies, are listing dozens of potential research projects they believe would help shorten the time it takes for new drugs to reach patients.